(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Tor-Bac Tor-Bac , Bacteriostatic Saline Solution for Injection - ( Unlicensed Medicine - Suggested Alternative: Sodium Chloride ) Strength: 0.9% Size: 10 x 5ml Form: Ampoules QuickFind Code: TORBAC Product Description Tor-Bac (Bacteriostatic Saline Solution for Injection) 5ml For Intramuscular/intradermal injection Contains Sodium Chloride 0.9% w/v Benzyl Alcohol 0.9% w/v Sodium chloride 0.9% with 9mg/ml benzyl alcohol (preservative) 30ml
Lab Findings: Vitamin D: 21 ng/mL (deficient) Vitamin B12: 198 pg/mL (deficient) Thyroid levels: Normal Treatment Plan: We implemented high-dose oral Vitamin D supplementation (under physician supervision), B12 injections for 10 weeks, and introduced microneedling sessions with growth serum every 3 weeks
The frequency varies based on individual response and medical advice, typically ranging from every few weeks to every few months
